Imara's Thalassemia Candidate Shows Reduced Transfusion Burden At Higher Dose

  • Imara Inc IMRA has announced data from a pre-specified interim analysis from its Forte Phase 2b trial of tovinontrine (IMR-687) in transfusion-dependent subjects (TDT) with beta-thalassemia.
  • Subjects in the Forte trial were randomized to either a lower dose group (200 mg or 300 mg), higher-dose group (300 mg or 400 mg), or placebo. 
  • The median baseline transfusion burden in each higher dose tovinontrine and placebo group was 7.5 red blood cell (RBC) units/12 weeks.
  • Interim data from the Forte study demonstrated tovinontrine was well-tolerated, with the most frequent adverse being nausea, headache, and dizziness. 
  • Four (9.3%) subjects discontinued due to adverse events considered related to the study drug.
  • The proportion of subjects who had over 33% reduction in transfusion burden (of at least two units) was greater in the higher dose tovinontrine group (7/8) versus placebo, despite an unexpectedly high response rate in the placebo group (8/12). 
  • Lower dose tovinontrine did not show a higher response rate when compared to the placebo group. No substantial differences between groups were observed in the transfusion burden response rate.
  • Additional data will be presented as part of a key efficacy analysis expected in Q1 of 2022.
  • Price Action: IMRA shares are up 1.11% at $3.63 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareTrading IdeasGeneralbeta thalassemiaBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!